Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial

Abstract We report on the randomized portion of the phase 2, open-label CheckMate 650 trial (NCT02985957), in which docetaxel-experienced, biologically male patients with chemotherapy-refractory metastatic castration-resistant prostate cancer were randomized 2:2:1:2 to nivolumab 3 mg /kg plus ipilim...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Padmanee Sharma, Michael Krainer, Fred Saad, Daniel Castellano, Jens Bedke, Mariusz Kwiatkowski, Akash Patnaik, Giuseppe Procopio, Paweł Wiechno, Samith Kochuparambil, Christian Thomas, José Ángel Arranz Arija, Steven L. McCune, Steinbjørn Hansen, Gedske Daugaard, Juan Ignacio Delgado Mingorance, Craig Kukard, Sumit K. Subudhi, Sreyashi Basu, Sonali Jindal, Bilal A. Siddiqui, Ana Lako, Saurabh Gupta, Viktor Fedorov, Neha P. Amin, Arancha Campos, Yumeng Wang, Justin M. David, Russell K. Pachynski
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Nature Portfolio 2026-05-01
Edice:	Nature Communications
On-line přístup:	https://doi.org/10.1038/s41467-026-72242-w
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!